Maja Katalinić

Zagreb, 31. listopada 1979.

• 1998.-2004. Prehrambeno-biotehnološki fakultet; studij: biotehnologija, smjer: biokemijsko inženjerstvo, Sveučilište u Zagrebu. “Usporedba djelovanja flavonoida na Lck i Fyn tirozinske kinaze ELISA metodom primjenom različitih supstrata: Poly Glu:Tyr (4:1) i M3-01 peptida” [diplomski rad] 2004. Mentori: Donatella Verbanac, Dubravko Jelić i Vladimir Mrša.
• 2006.−2011. Sveučilišni poslijediplomski doktorski studij kemije na Prirodoslovno-matematičkom fakultetu, smjer biokemija, Sveučilište u Zagrebu; “Učinkovitost bispiridinijevih oksima u reaktivaciji tabunom inhibiranih kolinesteraza” [doktorska disertacija]. Mentor: Zrinka Kovarik

• Od 2005. godine u Institutu za medicinska istraživanja i medicinu rada, Zagreb

Projekti

Voditelj

• 2025. − 2028. Istraživački projekt, “Boosting Synaptic Transmission with Pyridine and Nicotinamide Derivatives”, HrZZ-IP-2025-02-7665
• 2024. − 2027. WP1 koordinator “The influence of biologically active molecules on the nervous system”, BioMolTox “Assessment of effectiveness and toxicity of biologically active substances”, IMI Programme support; MZOM (PI, N. Maček Hrvat)
• 2018. − 2023. Uspostavni istraživački projekt, HrZZ „Molecular mechanisms underlying the toxicity of antidotes and potential drugs “ HrZZ-UIP-2017-05-7260
• 2020. − 2021. „ Effect of oxime analogues on skeletal muscle cell viability “; hrvatsko-slovenska bilateralna suradnja MZOM (PI M. Katalinić i S. Pirkmajer, SLO)
• 2014. − 2015. „The roll of a newly-identified NRE esterase in human muscle cells: profiling the enzyme as a predictor and/or therapeutic target for muscle related diseases”; hrvatsko-slovenska bilateralna suradnja MZOM (PI M. Katalinić i T. Marš, SLO)
• 2013. − 2014. „Mechanism of interactions of pyridinium oximes with acetylcholinesterases inhibited by OP compounds: kinetics, computational modelling and determination of complexes 3D structure”; COGITO hrvatsko-francuska bilateralna suradnja (PI M. Katalinić i F. Nachon, FR)

Partner

• 2024. − 2028. Horizon-EU: “Evolvable and rapidly adaptable monobodies: a broad-spectrum antiviral platform (EvaMobs)”; (PI C. M. Soares, PT)
• 2024. − 2027. EU-EDF: “European Strategic alliance for research, development and innovation on medical countermeasures against CBRN threats (RESILIENCE)” (PI C. Junot, FR)
• 2025. − 2026. “Modulation of neuromuscular transmission via skeletal muscle nicotinic receptors”; hrvatsko-slovenska bilateralna suradnja MZOM (PI A. Zandona)
• 2023. − 2025. “Application of hepatic 3D cell model (HepG2) for safety evaluation of newly synthesized oximes, antidotes in treatment of organophosphate poisoning (OximeSafe3D)”; hrvatsko-slovenska bilateralna suradnja MZOM (PI I. Vrhovac Madunić)

Istraživanje, profiliranje i identifikacija spojeva s terapijskim potencijalom za kolinergički sustav primjenom in silico i in vitro metoda te upotrebom staničnih modela; optimizacija eksperimenata radi smanjenja uporabe reagensa i dobivanja pouzdanih podataka za moguća in vivo ispitivanja.

• 2023. Visual communication of science (organizator Seyens Ltd., Ljubljana, Slovenia)
• 2022. EMBO Laboratory Leadership for Group Leaders (organizator EMBO)
• 2019./2020. Workshop on education, Better skills for better jobs: Education and training for successful research careers (organizatori HDBMB i FEBS)
• 2011. − 2012. poslijedoktorsko usavršavanje u Laboratoriju za molekularnu neorobiologiju Medicinskog fakulteta u Ljubljani, Slovenija (EMBO stipendija, stipendija Javnog sklada Republike Slovenije za razvoj kadrova i stipendije)

1. Zandona, Antonio; Szecskó, Anikó; Žunec, Suzana; Novak Jovanović, Ivana;  Bušić, Valentina;  Gašo Sokač, Dajana;  Deli, Mária A.; Katalinić, Maja;  Veszelka, Szilvia. Nicotinamide derivatives protect the blood-brain barrier against oxidative stress. Biomedicine & pharmacotherapy, 186 (2025), 118018, 12. doi: 10.1016/j.biopha.2025.118018
2. Zandona, Antonio; Jurić, Matea; Jean, Ludovic; Renard, Pierre-Yves; Katalinić, Maja. Assessment of cytotoxic properties of tetrahydroisoquinoline oximes in breast, prostate and glioblastoma cancer cells. Drug and chemical toxicology, 48 (2025), 2; 1-8. doi: 10.1080/01480545.2025.2491534
3. Žunec, Suzana; Vadlja, Donna; Ramić, Alma; Zandona, Antonio; Maraković, Nikola; Brekalo, Iva; Primožič, Ines; Katalinić, Maja. Profiling novel quinuclidine-based derivatives as potential anticholinesterase drugs: enzyme inhibition and effects on cell viability. International journal of molecular sciences, 25 (2024), 1; 155, 19. doi: 10.3390/ijms25010155
4. Zandona, Antonio; Madunić, Josip; Miš, Katarina; Maraković, Nikola; Dubois-Goeffroy, Pierre; Cavaco, Marco; Mišetić, Petra; Padovan, Jasna; Castanho, Miguel; Jean, Ludovic et al. Biological response and cell death signaling pathways modulated by tetrahydroisoquinoline-based aldoximes in human cells. Toxicology, 494 (2023), 153588-153602. doi: 10.1016/j.tox.2023.153588
5. Miš, Katarina; Lulić, Ana-Marija; Marš, Tomaž; Pirkmajer, Sergej; Katalinić, Maja. Insulin, dibutyryl-cAMP, and glucose modulate expression of patatin-like domain containing protein 7 in cultured human myotubes. Frontiers in endocrinology, 14 (2023), 1139303, 13. doi: 10.3389/fendo.2023.1139303

• Potpredsjednica Hrvatskog društva za biokemiju i molekularnu biologiju, HDBMB, 2025- danas, Tajnica HDBMB (2017-2021), Član Izvršnog odbora HDBMB-a
• Član Hrvatskog kemijskog društva
• Član Hrvatskog toksikološkog društva

Mentorstvo zadnjih 5 godina

3 doktoranda, 3 poslijedoktoranda